title: Somatostatin receptor scintigraphy in advanced renal cell carcinoma. Results of a phase II-trial of somatostatine analogue therapy in patients with advanced RCC.
abstract: OBJECTIVE
  Objective of this prospective study was to evaluate the role of somatostatin receptor scintigraphy (SRS) in advanced renal cell carcinoma (RCC) with respect to potential therapy with somatostatin analogue (SST-A) and to assess the response rate under therapy with SST-A.
  
  
  METHODS
  16 patients with documented progression of histologically confirmed advanced RCC were included. Planar whole-body SRS was performed 4, 24 and 48 h post i.v. injection of 175-200 MBq 111In-pentetreoide. 5 and 25 h p.i. SPECT of thorax and abdomen were performed. Documentation of somatostatin receptor expression via SRS in >50% of known tumour lesions was the criteria for treatment start with SST-A (Sandostatin LAR-Depot 30 mg i.m. every four weeks).
  
  
  RESULTS
  In 9/16 of the patients SRS showed at least one metastasis with moderate (n = 5) or intense (n = 4) tracer uptake. Lesion-based SRS evaluation showed only 12.1% (20/165) of all metastases. Most false-negative lesions were located in the lungs. In two patients, the majority of the known metastases was SRS positive and these patients received SST-A therapy. The first radiographic evaluation after a two-month interval showed progressive disease in both patients.
  
  
  CONCLUSIONS
  We conclude that SRS is of limited value in staging of advanced RCC. In our patients SST-A did not result in a growth control of RCC. Consequently, the use of SST-A in advanced RCC seems to be no relevant therapeutic option.
authors.affiliation: Department of Nuclear Medicine, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany. lutz.freudenberg@uni-due.de
authors.forename: L S
authors.initials: LS
authors.lastname: Freudenberg
authors.forename: T
authors.initials: T
authors.lastname: Gauler
authors.forename: R
authors.initials: R
authors.lastname: Görges
authors.forename: S
authors.initials: S
authors.lastname: Bauer
authors.forename: H
authors.initials: H
authors.lastname: Stergar
authors.forename: G
authors.initials: G
authors.lastname: Antoch
authors.forename: A
authors.initials: A
authors.lastname: Bockisch
authors.forename: J
authors.initials: J
authors.lastname: Schütte
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011877:Radionuclide Imaging / Q000379:methods*; D017481:Receptors, Somatostatin / Q000032:analysis*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome
chemical_list: D017481:Receptors, Somatostatin; D013004:Somatostatin